Novo’s Ozempic Linked to Lower Dementia Rate in Oxford Study

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s potential ancillary benefits.

After a year on Ozempic, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin, an older drug, as well as a lower risk of cognitive deficits compared with those who’d been on either sitagliptin or glipizide, another older medicine.